(S1 (S (S (NP (NP (NN p27) (NN phosphorylation)) (PP (IN by) (NP (NN Src)))) (VP (VBZ regulates) (NP (NP (NN inhibition)) (PP (IN of) (NP (NN cyclin) (NN E-Cdk2)))))) (. .)))
(S1 (S (S (NP (DT The) (NN kinase) (NN inhibitor) (NN p27Kip1)) (VP (VBZ regulates) (NP (DT the) (NN G1) (NN cell) (NN cycle) (NN phase)))) (. .)))
(S1 (S (S (ADVP (RB Here)) (, ,) (NP (PRP we)) (VP (VBP present) (NP (NP (NNS data)) (VP (VBG indicating) (SBAR (IN that) (S (NP (DT the) (JJ oncogenic) (NN kinase) (NN Src)) (VP (VBZ regulates) (NP (NN p27) (NN stability)) (PP (IN through) (NP (NP (NN phosphorylation)) (PP (IN of) (NP (NN p27))) (PP (IN at) (NP (NP (NN tyrosine) (CD 74)) (CC and) (NP (NN tyrosine) (CD 88))))))))))))) (. .)))
(S1 (S (S (S (NP (NN Src) (NNS inhibitors)) (VP (VBP increase) (NP (JJ cellular) (NN p27) (NN stability)))) (, ,) (CC and) (S (NP (NN Src) (NN overexpression)) (VP (VBZ accelerates) (NP (NN p27) (NN proteolysis))))) (. .)))
(S1 (S (S (S (NP (JJ Src-phosphorylated) (NN p27)) (VP (VBZ is) (VP (VBN shown) (S (VP (TO to) (VP (VB inhibit) (NP (NN cyclin) (NN E-Cdk2)) (ADVP (RB poorly)) (ADVP (FW in) (FW vitro)))))))) (, ,) (CC and) (S (NP (NN Src) (NN transfection)) (VP (VBZ reduces) (NP (NN p27-cyclin) (NN E-Cdk2) (NNS complexes))))) (. .)))
(S1 (S (S (NP (PRP$ Our) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (NN phosphorylation)) (PP (IN by) (NP (NN Src)))) (VP (VP (VBZ impairs) (NP (NP (DT the) (NN Cdk2) (JJ inhibitory) (NN action)) (PP (IN of) (NP (NN p27))))) (CC and) (VP (VBZ reduces) (NP (NP (PRP$ its) (JJ steady-state) (NN binding)) (PP (TO to) (NP (NN cyclin) (NN E-Cdk2))) (S (VP (TO to) (VP (VB facilitate) (NP (NN cyclin) (JJ E-Cdk2-dependent) (NN p27) (NN proteolysis)))))))))))) (. .)))
(S1 (S (S (ADVP (RB Furthermore)) (, ,) (NP (PRP we)) (VP (VBP find) (SBAR (IN that) (S (NP (JJ Src-activated) (NN breast) (NN cancer) (NNS lines)) (VP (VP (VBP show) (NP (VBN reduced) (NN p27))) (CC and) (VP (VBP observe) (NP (NP (DT a) (NN correlation)) (PP (IN between) (NP (NP (NP (NN Src) (NN activation)) (CC and) (NP (VBN reduced) (JJ nuclear) (NN p27))) (PP (IN in) (NP (CD 482) (JJ primary) (JJ human) (NN breast) (NNS cancers)))))))))))) (. .)))
(S1 (S (S (ADVP (RB Importantly)) (, ,) (NP (PRP we)) (VP (VBP report) (SBAR (IN that) (S (PP (IN in) (NP (JJ tamoxifen-resistant) (NN breast) (NN cancer) (NN cell) (NNS lines))) (, ,) (NP (NN Src) (NN inhibition)) (VP (MD can) (VP (VP (VB increase) (NP (NN p27) (NNS levels))) (CC and) (VP (VB restore) (NP (NN tamoxifen) (NN sensitivity))))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS data)) (VP (VBP provide) (NP (NP (DT a) (JJ new) (NN rationale)) (PP (IN for) (NP (NP (NN Src) (NNS inhibitors)) (PP (IN in) (NP (NN cancer) (NN therapy)))))))) (. .)))
